How Often Is UZEDY Administered for Schizophrenia?
UZEDY (risperidone) extended-release injectable suspension is approved for schizophrenia in adults. It is given subcutaneously every 1 or 2 months, depending on the dose strength and patient needs.[1]
- Monthly dosing: 50 mg, 75 mg, 100 mg, or 125 mg once every 4 weeks.
- Every 2 months dosing: 150 mg, 200 mg, 250 mg, or 300 mg once every 8 weeks.
Dosing starts with a single 50 mg dose (or 100 mg for faster steady-state), followed by the maintenance schedule after 4 weeks. Providers select based on response, tolerability, and prior oral risperidone dose.[1][2]
Why the 1-Month vs. 2-Month Options?
The formulation uses the Pathak IGY (in situ gel) technology, which provides sustained risperidone release over 1-2 months. Higher doses in larger volumes enable longer intervals, reducing injection frequency for better adherence in schizophrenia patients who often miss oral meds.[2][3]
What Happens During the First Month?
Patients typically continue oral antipsychotics for 3 weeks after the first UZEDY dose to avoid gaps in coverage while levels build. Do not start the next dose before 4 weeks.[1]
How Does UZEDY Compare to Other Long-Acting Schizophrenia Injectables?
| Medication | Dosing Frequency | Active Ingredient |
|------------|------------------|-------------------|
| UZEDY | Every 1-2 months | Risperidone |
| Risperdal Consta | Every 2 weeks | Risperidone |
| Invega Sustenna | Every 4 weeks (after loading) | Paliperidone |
| Invega Trinza | Every 3 months | Paliperidone |
| Abilify Maintena | Every 4 weeks | Aripiprazole |
UZEDY stands out for flexible 1- or 2-month options and no oral supplementation after the first month, unlike some competitors.[2][4]
Can Dosing Change Over Time?
Yes, providers may adjust between monthly and bimonthly based on efficacy, side effects, or PK levels. No loading dose is required for 2-month initiation if switching from oral risperidone.[1]
Common Patient Questions on Administration
- Injection site: Upper arm, abdomen, or buttocks; rotate sites.
- Missed dose: Administer as soon as possible, then resume schedule.
- Who gives it?: Healthcare professionals only; self-administration not approved.
No patents listed on DrugPatentWatch.com for UZEDY's core formulation, but check for updates on delivery tech.[5]
[1] UZEDY Prescribing Information, Teva Pharmaceuticals, 2023. https://www.uzedyhcp.com/
[2] FDA Approval Summary, UZEDY, April 2023. https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/213735s000lbl.pdf
[3] Clinical Pharmacology Review, NDA 213735. https://www.accessdata.fda.gov/drugsatfdadocs/nda/2023/213735Orig1s000ClinPharmR.pdf
[4] Schizophrenia Treatment Guidelines, APA, 2020 (comparative data).
[5] DrugPatentWatch.com, UZEDY (risperidone). https://www.drugpatentwatch.com/p/tradename/UZEDY